RxMP is dedicated to developing innovative therapies to prevent and treat hemorrhage and excessive bleeding. Our platform technology capitalizes on the finding that RMPs, when administered systemically in the setting of acute bleeding, will stop the bleeding while having little risk of undesirable clotting elsewhere in the body. RxMP’s lead product program has been funded by approximately $11 million in grants and $5.5 million of investment to-date directed at substantially de-risking the RMP product platform and its development program. RxMP’s lead product, RMP-402, has a multibillion-dollar market potential, if successful, in preventing and treating excessive bleeding and hemorrhage.